ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Diagnostic criteria for corticobasal degeneration*

Diagnostic criteria for corticobasal degeneration*
  Clinical research criteria for probable sporadic CBD Clinical criteria for possible CBD
Presentation Insidious onset and gradual progression Insidious onset and gradual progression
Minimum duration of symptoms, years 1 1
Age at onset, years ≥50 No minimum
Family history (two or more relatives) Exclusion Permitted
Permitted phenotypes
  1. Probable CBS
    or
  2. FBS or NAV plus at least one CBS feature:
    • Limb rigidity or akinesia
    • Limb dystonia
    • Limb myoclonus
    • Orobuccal or limb apraxia
    • Cortical sensory deficit
    • Alien limb phenomena
  1. Possible CBS
    or
  2. FBS or NAV
    or
  3. PSPS plus at least one CBS feature:
    • Limb dystonia
    • Limb myoclonus
    • Orobuccal or limb apraxia
    • Cortical sensory deficit
    • Alien limb phenomena
Genetic mutation affecting tau (eg, MAPT) Exclusion Permitted

CBD: corticobasal degeneration; CBS: corticobasal syndrome; FBS: frontal behavioral-spatial syndrome; MAPT: microtubule-associated protein tau; NAV: nonfluent/agrammatic variant of primary progressive aphasia; PSPS: progressive supranuclear palsy syndrome.

* Exclusion criteria for both clinical research criteria for probable sporadic CBD and possible CBD:
  1. Evidence of Lewy body disease: classic 4 Hz Parkinson disease resting tremor, excellent and sustained levodopa response, or hallucinations.
  2. Evidence of multiple system atrophy: dysautonomia or prominent cerebellar signs.
  3. Evidence of amyotrophic lateral sclerosis: presence of both upper and lower motor neuron signs.
  4. Semantic- or logopenic-variant primary progressive aphasia.
  5. Structural lesion suggestive of focal cause.
  6. Granulin mutation or reduced plasma progranulin levels; TDP-43 mutations; FUS mutations.
  7. Evidence of Alzheimer disease (this will exclude some cases of CBD with coexisting amyloid; data from one brain bank suggest that excluding cases with evidence of amyloid may result in missing approximately 14% of CBD cases [Dickson D, 2012, personal communication]): laboratory findings strongly suggestive of Alzheimer disease such as low cerebrospinal fluid beta-amyloid 42-to-tau ratio or positive 11C-Pittsburgh compound B PET; or genetic mutation suggesting Alzheimer disease (eg, presenilin, amyloid precursor protein).

¶ Possible CBD emphasizes clinical presentations consistent with CBD but ones that may also overlap with other tau-based pathologies.

From: Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80:496. DOI: 10.1212/WNL.0b013e31827f0fd1. Copyright © 2013 American Academy of Neurology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.
Graphic 98951 Version 7.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟